🇺🇸 FDA
Pipeline program

A research study to look at how CagriSema influences food intake, appetite and emptying of the stomach in people with excess body weight

NN9838-4695

Phase 1 other active

Quick answer

A research study to look at how CagriSema influences food intake, appetite and emptying of the stomach in people with excess body weight for Obesity is a Phase 1 program (other) at Novo Nordisk A/S with 1 ClinicalTrials.gov record(s).

Program details

Company
Novo Nordisk A/S
Indication
Obesity
Phase
Phase 1
Modality
other
Status
active

Clinical trials